Overview
Lobbying Costs
200,000€ - 299,999€
Financial year: Jan 2023 - Dec 2023
Lobbyists (Full time equivalent)
0.5 Fte (2)
Lobbyists with EP accreditation
0
High-level Commission meetings
1
Lobbying Costs over the years
-
Info
International Pharmaceutical Aerosol Consortium (IPAC)
EU Transparency Register
602537137644-70 First registered on 16 Mar 2020
Goals / Remit
The International Pharmaceutical Aerosol Consortium (IPAC) was formed in 1989 in response to the mandates of the Montreal Protocol on Substances that Deplete the Ozone Layer and fully supported a timely and effective transition away from chlorofluorocarbons (CFCs) used in pressurised metered dose inhalers (pMDIs) under the Montreal Protocol that balanced patient health and environmental concerns. IPAC’s mission is to ensure that environmental policies relevant to inhaled therapies are patient-centric and appropriately balance both patient care and sustainability objectives. IPAC members research and develop CFC-free products – HFC pMDIs, dry powder inhalers (DPIs) and soft mist inhalers (SMIs). In light of this history and deep expertise, IPAC is uniquely positioned to serve as a resource in efforts related to the intersection of environmental policies and inhaled therapies. IPAC’s members are AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GSK, Kindeva, Organon & Teva.
Main EU files targeted
IPAC's focus is on environmental/climate change policies related to fluorinated gases and, in particular, hydrofluorocarbons (HFCs) 134a and 227ea which are used as aerosol propellants in inhaled therapies. IPAC is engaging with the Commission and other stakeholders on the review of the European F-Gases Regulation: Regulation (EU) No 517/2014 of the European Parliament and of the Council of 16 April 2014 on fluorinated greenhouse gases.
Address
Head Office
1500 K Street, NW Suite 1100
Washington 20005
UNITED STATESEU Office
1500 K Street, NW Suite 1100
Washington 20005
UNITED STATESWebsite
-
People
Total lobbyists declared
2
Employment time Lobbyists 25% 2 Lobbyists (Full time equivalent)
0.5
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Trade and business associations
-
Networking
Affiliation
IPAC is an associate member of the Alliance for Responsible Atmospheric Policy, please see: http://alliancepolicy.org/.
Member organisations
IPAC’s members are AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GSK, Kindeva, Organon, and Teva. See www.ipacinhaler.org.
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2023 - Dec 2023
Lobbying costs for closed financial year
200,000€ - 299,999€
Major contributions in closed year
None declared
Intermediaries for closed year
None declaredIntermediaries for current year
Name fti consulting Closed year Costs
200,000€ - 299,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
Consultation Forum according to Art. 23 of Regulation (EU) No 517/2014 on fluorinated greenhouse gases#X03338#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=3338 #Member #C#Industry, Civil society
Groups (European Parliament)
Climate change, biodiversity and sustainable development
Communication activities
IPAC's activities in 2023 are summarized below.
IPAC has engaged with the European Commission, staff/members of Parliament, and Council on issues relevant to the use of HFCs as medical propellants. We submitted a joint stakeholder letter to many senior EU policymakers in January 2023. A copy of the letter is posted on IPAC's website: www.ipacinhaler.org.
IPAC also responded to a public questionnaire on ECHA Reach/PFAS issues in May and September. A copy is available on www.ipacinhaler.org.Other activities
None declared
- Meetings
Meetings
1 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.
-
Date 09 Nov 2021 Location video conference Subject Fluorinated Gases regulation Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis Portfolio An Economy that Works for People Attending - Caroline Boeshertz (Cabinet member)
- Meetings